title: Targeting delivery of liposomes with conjugated p-aminophenyl-α-d-manno-pyranoside and apolipoprotein E for inhibiting neuronal degeneration insulted with β-amyloid peptide.
abstract: Liposomes with conjugated p-aminophenyl-α-d-manno-pyranoside (APMP) and apolipoprotein E (ApoE) (APMP-ApoE-liposomes) were employed to carry neuron growth factor (NGF) across the blood-brain barrier (BBB) and enhance the survival of degenerated neurons. APMP-ApoE-liposomes were used to deliver NGF across a monolayer of human brain-microvascular endothelial cells (HBMECs) regulated by human astrocytes (HAs) for rescuing SK-N-MC cells from an insult of β-amyloid peptide 1-42 (Aβ1-42). An increase in the APMP concentration enhanced the particle size, HBMEC and HA viability, permeability for propidium iodide (PI), and permeability for NGF, however, reduced the absolute value of zeta potential, APMP conjugation efficiency and transendothelial electrical resistance (TEER). In addition, an increase in the ApoE concentration increased the particle size, absolute value of zeta potential, HBMEC and HA viability, permeability for PI, permeability for NGF and SK-N-MC cell viability, however, decreased the ApoE conjugation efficiency and TEER. APMP and ApoE on liposomes can be promising surface moieties to carry NGF across the BBB, target degenerated neurons and inhibit Aβ1-42-induced neurotoxicity in Alzheimer's disease.
authors.affiliation: Department of Chemical Engineering, National Chung Cheng University , Chia-Yi, Taiwan , Republic of China.
authors.forename: Yung-Chih
authors.initials: YC
authors.lastname: Kuo
authors.forename: Che-Yu
authors.initials: CY
authors.lastname: Lin
mesh_terms: D016229:Amyloid beta-Peptides / Q000378:metabolism* / Q000494:pharmacology; D000814:Aniline Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D001057:Apolipoproteins E / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D001253:Astrocytes / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000378:metabolism; D018929:Cell Culture Techniques; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008081:Liposomes; D008362:Mannosides / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D009414:Nerve Growth Factors / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D010316:Particle Size; D010446:Peptide Fragments / Q000378:metabolism* / Q000494:pharmacology; D010539:Permeability
chemical_list: D016229:Amyloid beta-Peptides; D000814:Aniline Compounds; D001057:Apolipoproteins E; D008081:Liposomes; D008362:Mannosides; D009414:Nerve Growth Factors; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); C034056:4-aminophenylmannoside
keywords: Alzheimer’s disease; apolipoprotein E; blood–brain barrier; liposome; neuron growth factor; p-aminophenyl-α-d-manno-pyranoside; β-Amyloid peptide